Faslodex 500mg Multiple Dose Tolerability Study in BC Patients
Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the tolerability of 500mg fulvestrant in
postmenopausal women with hormone receptor positive, advanced or recurrent breast cancer